Literature DB >> 17433872

PD-1 and its ligands in T-cell immunity.

Mary E Keir1, Loise M Francisco, Arlene H Sharpe.   

Abstract

The past year has seen significant advances in our understanding of the critical roles of negative immunoregulatory signals delivered by the programmed death 1 (PD-1)-PD-1 ligand (PD-L) pathway in regulating T-cell activation and tolerance. Emerging evidence indicates that PD-Ls play an essential role on dendritic cells (DCs), both directly during DC-T cell interactions and indirectly through signaling into the DC. Recent studies point to a novel role for PD-L1 in maintaining tissue tolerance. Finally, PD-1 has recently been shown to be highly expressed on exhausted T cells during chronic viral infection, and blockade of PD-1 or PD-L1 can revive exhausted T cells, enabling them to proliferate and produce effector cytokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433872     DOI: 10.1016/j.coi.2007.04.012

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  178 in total

1.  Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men.

Authors:  Mohammad Reza Zamani; Firouzeh Akbari Asbagh; Amir Hossein Massoud; Arash Salmaninejad; Ahmad Massoud; Nima Rezaei
Journal:  J Assist Reprod Genet       Date:  2014-11-16       Impact factor: 3.412

2.  Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance.

Authors:  Joseph A Conrad; Ramesh K Ramalingam; Coley B Duncan; Rita M Smith; Jie Wei; Louise Barnett; Brenna C Simons; Shelly L Lorey; Spyros A Kalams
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

Review 3.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

Review 4.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

5.  Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1.

Authors:  Chunhe Wang; Babak Dehghani; Yuexin Li; Laurie J Kaler; Thomas Proctor; Arthur A Vandenbark; Halina Offner
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.

Authors:  A Singh; A Mohan; A B Dey; D K Mitra
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

Review 7.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

Review 8.  Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.

Authors:  Alessia Mennitto; Paolo Grassi; Raffaele Ratta; Elena Verzoni; Michele Prisciandaro; Giuseppe Procopio
Journal:  Ther Adv Urol       Date:  2016-07-07

9.  Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.

Authors:  Michael G Hanna; Jason Howard; Jan Vermorken
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.

Authors:  Mohammad Rashidian; Martin W LaFleur; Vincent L Verschoor; Anushka Dongre; Yun Zhang; Thao H Nguyen; Stephen Kolifrath; Amir R Aref; Christie J Lau; Cloud P Paweletz; Xia Bu; Gordon J Freeman; M Inmaculada Barrasa; Robert A Weinberg; Arlene H Sharpe; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.